Pharming Group (NASDAQ:PHAR) Shares Gap Down – Should You Sell?

Shares of Pharming Group (NASDAQ:PHAR) gapped down before the market opened on Tuesday . The stock had previously closed at $10.01, but opened at $9.48. Pharming Group shares last traded at $9.47, with a volume of 1,070 shares traded.

Wall Street Analyst Weigh In

PHAR has been the topic of a number of research analyst reports. Oppenheimer dropped their price objective on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, October 28th. HC Wainwright restated a “buy” rating and issued a $37.00 price target on shares of Pharming Group in a report on Tuesday, December 17th. Finally, Jefferies Financial Group began coverage on Pharming Group in a report on Monday, December 9th. They set a “buy” rating and a $14.00 price objective for the company.

Pharming Group Trading Up 2.2 %

The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The business’s 50-day moving average is $8.95 and its two-hundred day moving average is $8.41. The firm has a market cap of $630.19 million, a P/E ratio of -35.73 and a beta of -0.08.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its stake in Pharming Group (NASDAQ:PHAR) by 16.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the quarter. Silverberg Bernstein Capital Management LLC owned approximately 0.07% of Pharming Group worth $483,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.